WO2007121662A1 - Dérivés de diphénylurée utilisés comme inhibiteurs de kinase, compositions et utilisations de ceux-ci - Google Patents

Dérivés de diphénylurée utilisés comme inhibiteurs de kinase, compositions et utilisations de ceux-ci Download PDF

Info

Publication number
WO2007121662A1
WO2007121662A1 PCT/CN2007/001227 CN2007001227W WO2007121662A1 WO 2007121662 A1 WO2007121662 A1 WO 2007121662A1 CN 2007001227 W CN2007001227 W CN 2007001227W WO 2007121662 A1 WO2007121662 A1 WO 2007121662A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
group
alkyl
pharmaceutically acceptable
Prior art date
Application number
PCT/CN2007/001227
Other languages
English (en)
Chinese (zh)
Inventor
Dingqi Wan
Original Assignee
Suzhou Ascepion Pharmaceuticals, Inc.
Du, Kun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Ascepion Pharmaceuticals, Inc., Du, Kun filed Critical Suzhou Ascepion Pharmaceuticals, Inc.
Publication of WO2007121662A1 publication Critical patent/WO2007121662A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Definitions

  • Diphenylurea derivative for inhibiting protein kinase for inhibiting protein kinase, composition and use thereof
  • the invention relates to the field of medicine.
  • the invention relates to diphenylurea derivatives for inhibiting protein kinases, as well as to compositions and uses thereof. Background technique
  • Protein kinase is the largest family of human enzyme proteins, with more than 500 proteins.
  • Peptidase plays an important role in the process of angiogenesis.
  • Vascular growth is the process of forming new blood vessels based on existing blood vessels. This process plays a very important role in many pathological processes. These pathological processes include cancer, chronic immune diseases, diabetic retinopathy, psoriasis, rheumatoid arthritis, and macular degeneration.
  • Anti-angiogenic therapy represents a potentially important means of treating solid tumors and other diseases associated with vascular growth disorders. The benefits of anti-angiogenic therapy in the clinical treatment of the disease are becoming more apparent from the approval of the use of a series of anti-angiogenic drugs (such as Avastin, Nexavar and Sutent). ,
  • vascular endothelial growth factor vascular endothelial growth factor
  • FGF fibroblast growth factor
  • PDGF platelet-derived growth factor
  • Receptors corresponding to these vascular growth regulators including vascular endothelial growth factor receptors (VEGF receptors or VEGFRs), fibroblast growth factor receptors (FGF receptors or FGFRs), and vascular protein 1 and 2 receptors Tiel And Tie2, and PDGF receptor PDGFR a and PDGFR have also been discovered.
  • VEGFRs, FGFRs, Tiel and Tie2 were expressed on the surface of vascular endothelial cells
  • PDGFR a was expressed on the surface of vascular stromal cells secreting VEGF
  • PDGFR 3 was expressed on the surface of perivascular cells and smooth muscle cells.
  • the above various protein molecules including VEGF, FGF, PDGF, VEGFRs, FGFRs, PDGFRs, Tiel and Tie2 together constitute a complex molecular signaling network. This signaling network plays an important role in regulating and controlling blood vessel growth under physiological and pathological conditions (see review Caraieliet, R, 2005).
  • vascular growth regulatory signaling molecules such as VEGF and FGF
  • vascular growth-blocking methods such as monoclonal antibodies
  • vascular growth blocking method designed for multiple signal paths at the same time should produce good results. Therefore, the development of a multi-targeted multiplex small molecule kinase inhibitor is an effective way to achieve high efficiency of vascular growth blockade (see review Ferrara, N. and Kerbel, R., 2005).
  • small molecule compounds that can be simultaneously screened to inhibit multiple protein kinases can effectively block angiogenesis in tumors, thereby delaying or interrupting tumor growth.
  • US Food and Drug Administration USFDA
  • US FDA New Drug Database http: ⁇ www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfin; Sutent: FDA NDA #021938 and #021968; Nexavar: FDA NDA #021923 ).
  • Nexavar is used for the treatment of advanced kidney cancer, while Sutent is used to treat advanced kidney cancer and gastrointestinal stromal cancer (GIST).
  • GIST gastrointestinal stromal cancer
  • VEGFR2 (D) and PDGFR P are drug targets of Nexavar and Sutent
  • the clinical efficacy of Nexavar and Sutent undoubtedly demonstrates the value of inhibiting the activity of VEGRF2 (KDR) and PDGRFR beta in the treatment of diseases such as cancer ( Rini, BI, 2006; Motzer, RJ. et al., 2006). Therefore, from a pharmaceutical point of view, the development of multiplexed small molecule protein kinase inhibitors against VEGFR2 (KDR) and PDGFR P is very valuable for the treatment of cancer and other diseases associated with blood vessel growth.
  • the international patent publication WO 00/09495 discloses an isoquinoline derivative Vatalanib (VEGFR inhibitor) having the structure of the following formula which inhibits angiogenic activity.
  • an aspect of the present invention provides a compound having the following formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof,
  • ⁇ ⁇ ⁇ 2 are each independently selected from CH and ⁇ ;
  • R7 is a substituted or unsubstituted aryl or heteroaryl group
  • ZBZ 3 is - CR 9 R 1D -, wherein 19 and R 1D are each independently selected from a hydrogen atom, a substituted or unsubstituted C r C 3 alkyl, and halo;
  • Z 2 is absent or is selected from -O-, -S -, -NR -, wherein R is selected from H and -C3 fluorenyl;
  • n and m are integers from 0 to 2;
  • R1 is absent or represents 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of: hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl, halo, carboxy , substituted or unsubstituted acyl group, substituted or unsubstituted alkoxycarbonyl group, substituted or unsubstituted c 3 fluorenyl group, substituted or unsubstituted c r c 3 decyloxy group, sulfonyl group, sulfinyl group, sulfonyl group;
  • R4 is absent or represents 1, 2, 3, 4 or 5 substituents, each substituent being independently selected from the group consisting of: hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl , halogenated, carboxy, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted C 6 alkyl, taken Substituted or unsubstituted ⁇ - (6 alkoxy group, a substituted or unsubstituted aryloxy group, sulfonamide group, sulfinyl group, a sulfonyl group, a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted a heteroaromatic hydrocarbon group, a substituted or unsubstituted heterocyclic fluorenyl group; or an adjacent two R4 groups together with a carbon atom to be bonded to form
  • compositions comprising an effective amount of a compound of the invention or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is formulated in a form selected from the group consisting of an injection, an aerosol, a cream, a gel, a tablet, a pill, a capsule, a syrup, an eye drop, or Skin plaster.
  • Still another aspect of the invention relates to the use of the above compound, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the manufacture of a medicament for the treatment of a disease responsive to inhibition of a protein kinase.
  • the disease is selected from the group consisting of: tumor, rheumatoid arthritis, arterial restenosis, autoimmune disease, acute inflammation, acute and chronic nephritis, diabetic retinopathy, psoriasis, or macular degeneration.
  • the present invention provides that certain compounds can significantly inhibit the biological activity of at least one of VEGFR2 and PDGFR P. Since the clinical efficacy of Nexavar and Sutent confirms the value of VEGFR2 and PDGFR P as drug targets (Rini, BI, 2006; Motzer, RJ et al, 2006), the inhibitory potency of these compounds for multiple targets or one of them It has a very high medical value for the treatment of diseases related to blood vessel growth. Diseases that can benefit from the therapeutic effects of these compounds include cancer (Gasparini, G. et al., 2005), rheumatoid arthritis (Taylor, PC & Sivakumar, B. 5 2005; Szekanecz, Z.
  • Chemical formula (I) contains all sub-chemical formulas. When a symbol appears multiple times in a chemical formula, the definition of each occurrence of the symbol is independent of the definition at any other time.
  • mercapto includes both straight and branched chains having the specified number of carbon atoms.
  • cvc 5 alkyl represents both straight and branched chains having from 1 to 5 carbon atoms.
  • alkyl group in the present invention include: methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, Hexyl, 2-hexyl, 3-hexyl, 3-methylhexyl and the like.
  • the fluorene group belongs to another subset of sulfhydryl groups, meaning that it has the same residue as the alkyl group but has two points of attachment.
  • C Q fluorenylene means a covalent bond
  • an anthranylene group is a methylene group.
  • all geometric isomers with the same number of carbon atoms are included.
  • the term "butyl” includes n-butyl, sec-butyl, isobutyl, and tert-butyl
  • the term "propyl” includes n-propyl and isopropyl
  • "lower thio" contains one. a sulfhydryl group to four carbon atoms.
  • “Mercaptooxy” refers to a fluorenyl group having the specified number of carbon atoms attached to the parent structure through an oxygen atom bridge, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, Sec-butoxy, tert-butoxy, pentyloxy, 2-pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, 2-hexyloxy, 3-hexyloxy, 3-methyl Pentyloxy, and the like.
  • “Lower decyloxy” means an alkoxy group having from one to four carbon atoms.
  • Alkylthio refers to an alkyl group having the specified number of carbon atoms attached to the parent structure through a sulfur linkage. "Lower alkylthio” means a decyloxy group having from one to four carbon atoms.
  • Acyl includes a group (alkyl) -C(0)-, (cyclodecyl)-C(0)-, (aryl)-C(0)-, (heteroaryl)-C(O) - and (heterocyclic fluorenyl) -C(O)-.
  • This group is attached to the parent structure by the function of a carbonyl group, meaning that an alkyl group as defined above is attached to the parent structure via a keto group (-(OO)-).
  • the number of carbon atoms of the acyl group contains the carbon atoms carried by the ketone group.
  • C r C 6 ⁇ oxycarbonyl represents a decyloxy group having 1 to 6 carbon atoms which is bonded to a carbonyl group through its oxygen atom.
  • Amino refers to a -NH 2 group.
  • “Mono- and bis-alkylamino” embraces both secondary and tertiary mercaptoamino groups, wherein the alkyl group is as defined above and There are a specified number of carbon atoms. The point of attachment of the mercaptoamino group to the parent structure is at the nitrogen atom.
  • Examples of the mono- and di-alkylamino groups include ethylamino, dimethylamino, and methylpropylamino.
  • “Mono- and bis-alkylaminoalkyl” represents a group consisting of a mono- and bis-indenylamino group as defined above attached to an alkyl group.
  • aminosyl refers to a group consisting of an amino group attached to an alkyl group of the specified number of carbon atoms.
  • hydroxyindenyl is a group consisting of a hydroxyl group attached to a thiol group.
  • aminocarbonyl refers to a -CONR b R° group, wherein R b is selected from H, substituted or unsubstituted d-Ce alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl R e is selected from hydrogen and a substituted or unsubstituted CC 4 alkyl group; or R b and R e and a nitrogen atom bonded thereto constitute a substituted or unsubstituted 5 to 7 membered nitrogen-containing heterocycloalkyl group, which is hetero
  • the cycloalkyl group may also optionally contain 1 or 2 additional heteroatoms selected from O, N or S; each substituent is independently selected from the group consisting of: CC 4 alkyl, aryl, heteroaryl, aromatic -Alkyl-, heteroaryl-C r C 4 fluorenyl-, -C 4 halodecyl-, -O VC
  • Aryl includes: a 5- or 6-membered aromatic carbon atom ring (such as a phenyl group), at least one of which is an aromatic carbon ring ring bicyclic structure (such as naphthyl, indanyl, and tetrahydronaphthyl) And a tricyclic structure (such as a fluorenyl group) in which at least one of them is an aromatic carbon atom ring.
  • an aryl group comprises a structure in which a 5 and 6 membered aromatic carbon atom ring is fused to a 5 to 7 membered heteroalkyl ring, wherein the heterofluorenyl ring contains one or more (eg 1, 2 or 3).
  • a fused bicyclic structure in which only one ring is an aromatic carbon atom ring its point of attachment to the parent structure may be either in the aromatic carbon atom ring or in the heteroalkyl ring.
  • the divalent group formed by the free valence of the substituted benzene derivative and the atom on the ring is referred to as a substituted polyphenyl group.
  • the name of the divalent group resulting from the removal of one hydrogen atom from a free-valent carbon atom in a monovalent polycyclic hydrocarbon group is preceded by the word "sub", for example, having two points of attachment.
  • Naphthyl is referred to as a naphthylene group.
  • the aryl group contains neither a heteroaryl group nor a definition of a heteroaryl group.
  • Heteroaryl groups will be defined separately below. If one or more aromatic carbon atom rings are fused to an aromatic heterofluorenyl ring, the resulting ring structure belongs to heteroaryl The base is not within the aryl range defined herein.
  • aryloxy refers to the group -O-aryl.
  • halo includes fluoro, chloro, bromo, iodo.
  • halogen includes fluorine, chlorine, bromine, and iodine.
  • Haloalkyl means an alkyl group, as defined above, having the specified number of carbon atoms, substituted with one or more halogen atoms.
  • the number of substituted halogen atoms can generally be as large as the maximum allowable number.
  • Examples of halohydrazino groups include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, and pentafluoroethyl.
  • Heteroaryl comprises: a 5 to 7 membered aromatic monocyclic structure containing one or more (eg 1 to 4, or in some embodiments 1 to 3) selected from N, O And a hetero atom of S and the remaining ring atom is a carbon atom; and a bicyclic heteroalkyl ring containing one or more (for example 1 to 4, or in some embodiments 1 to 3) selected from The hetero atoms of N, 0 and S and the remaining ring atoms are carbon atoms, and one aromatic ring contains at least one hetero atom.
  • the heteroaryl group has a structure in which a 5- to 7-membered aromatic heteroalkyl ring is fused to a 5- to 7-membered alkyl ring.
  • the point of attachment to the parent structure can be either on the heteroaromatic ring or on the alkyl ring.
  • the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms cannot be adjacent.
  • the total number of S and 0 atoms in the heteroaryl group does not exceed two.
  • the total number of S and O atoms in the aromatic heterocycle does not exceed one.
  • heteroaryl groups include, but are not limited to, structural systems (where the point of attachment is designated as 1, and the rest of the positions are by sequence number) such as 2-pyridyl, 3-pyridyl, 4-pyridyl, 2,3-pyrazinyl, 3 , 4-pyrazinyl, 2,4-pyrimidinyl, 3,5-pyrimidinyl, 2,3-pyrazolyl, 2,4-imidazolinyl, isoxazolyl, oxazolinyl, thiazole Polinyl, thiadiazolyl, tetrazolinyl, dithienyl, benzothiophenyl, furyl, benzofuranyl, benzimidazolyl, porphyrin, pyridazine, Triazolyl, quinolyl, pyrazolyl, and 5,6,7,8-tetrahydroisoquinoline.
  • structural systems where the point of attachment is designated as 1, and the rest of the positions are by sequence number
  • a divalent group resulting from the removal of a hydrogen atom from an atom having a free valence in a monovalent heteroaryl group is preceded by the word "sub", for example, a pyridyl group having two points of attachment. It is a pyridylene group.
  • a heteroaryl group contains neither an aryl group nor an overlap with the definition of an aryl group.
  • heteroaromatic hydrocarbon and alkyl group in the term "heteroarylalkyl” are as defined above, and the point of attachment to the parent structure is on the alkyl group.
  • the term includes, but is not limited to, pyridylmethyl, thiobenzyl, and (pyrrolyl) 1-ethyl.
  • Heterocycloalkyl means a single aliphatic ring structure containing at least 2 carbon atoms and 1 to 3 heteroatoms, wherein each heteroatom is independently selected from the group consisting of oxygen, sulfur and nitrogen, or a combination of heteroatoms At least one of these three atoms.
  • suitable heterocycloalkyl groups include (the position of the point of attachment is specified as 1, and the remaining positions are arranged in order) 2-pyrroline, 2,4-imidazolidinyl, 2,3-pyrazolyl, 2-piperidinyl 3-piperidinyl, 4-piperidinyl and 2,5-piperazinyl.
  • Morpholinyl also belongs to this class, which includes 2-morpholinyl and 3-morpholinyl (oxygen is designated as the 1-position).
  • alkylthio embraces the following groups: -S-(substituted or unsubstituted alkyl), -S- (substituted or unsubstituted aryl), -S- (substituted or unsubstituted heteroaryl) And -S- (substituted or unsubstituted heterocyclic fluorenyl). Therefore, the sulfonyl group contains ( ⁇ -( 6 ⁇ thio group).
  • sulfinyl embraces the following groups: - S(O)-H, -S(O)- (substituted or unsubstituted fluorenyl), -S(O)- (substituted or unsubstituted aryl) , -S(O)- (substituted or unsubstituted heteroaryl), -S(O)- (substituted or unsubstituted heterocyclic fluorenyl); and -S(O)- (substituted or unsubstituted) Amino).
  • sulfonyl embraces the following groups: -S(O 2 )-H, -S(O 2 )- (substituted or unsubstituted fluorenyl), -S(O 2 )- (substituted or unsubstituted) Aryl), -S(O 2 )- (substituted or unsubstituted heteroaryl), -S(O 2 )- (substituted or unsubstituted heterocycloalkyl), -s(o 2 )- (substituted Or unsubstituted alkoxy), -s(o 2 M substituted or unsubstituted aryloxy), -S(O 2 ) -(substituted or unsubstituted heteroaryloxy), -8(0 2 ) - (substituted or unsubstituted heterocyclic oxy); and -S(O 2 )- (substituted or un
  • substituted is used herein to mean: Replace a specified atom or group of any one or more hydrogen atoms with a selected group of atoms, but the number of substitutions must not exceed the price of the specified atom. number.
  • two hydrogen atoms on the designated atom will be replaced.
  • Combinations of such substituents and/or chemical formulas are permissible only if the combination of substituents and/or chemical formulas results in a stable compound or an intermediate of a useful synthetic reaction.
  • a stable compound or structure means that a compound has sufficient stability so that the compound can be separated from the reaction mixture and used as a component for practical use in the subsequent formulation.
  • substituted alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl each represent alkyl, cyclodecyl, aryl, heterocycloalkyl, and heteroaryl, respectively.
  • -R -OR b -O(CVC 2 fluorenyl) O- (for example, dioxymethane-), -SR b , fluorene, hydrazine, -NR b in which one or more hydrogen atoms are replaced by a lower alkyl group R.
  • R a is selected from a substituted or unsubstituted CC 6 alkyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group;
  • R 13 is selected from hydrogen and a substituted or unsubstituted C r C 4 alkyl group;
  • Each substituted or unsubstituted group is either unsubstituted or each independently substituted with one or more (eg, 1 or 2 or 3) substituents, each substituent being independently selected from the group consisting of: C r C 4 fluorenyl, aryl, heteroaryl, aryl-C decyl-, heteroaryl-C r C fluorenyl-, C r C4 halogenated fluorenyl-, -O VC 4 alkyl, -O VC 4 hydrocarbon phenyl, -alkyl-OH, -OC!-Ct haloalkyl, halo, -OH, -NH 2 , -dC 4 alkyl-NH 2 , -N(C r C 4 alkyl) (Cr fluorenyl), - ⁇ (( ⁇ 4 fluorenyl), -NCC alkyl) (CVC 4 hydrocarbon phenyl), -NHCC C4 hydrocarbon phenyl
  • Substituted acyl means a group: (substituted alkyl) -C(O)-, (substituted cyclodecyl) -C(0)-, (substituted aryl) -C( O)-, (substituted heteroaryl)-C(O)- and (substituted heterocyclic fluorenyl)-C(O)-.
  • alkyl group, cycloalkyl group, aryl group, heteroaryl group and heterocycloalkyl group each represent a fluorenyl group, a cycloalkyl group, an aryl group, a heteroaryl group and a hetero group, respectively.
  • -R -OR b -0 (CVC alkyl) 0- (for example, dioxymethane-), -SR b , fluorene, hydrazine, -NR b R in which one or more hydrogen atoms are replaced by a lower alkyl group e , halo, cyano, nitro, -COR b , -C0 2 R b , -CONR b R e , -OCOR b , -OC0 2 R a , -OCONR b R°> -NR c COR b , - NR c CO 2 R a , -NR c CONR b R -CO 2 R b , -CONR b R c , -NR c COR b , -SOR a , - SO 2 R a , -SO 2 NR b R c and - NR c SO 2 R a ,
  • R A is selected from a substituted or unsubstituted C R C 6 alkyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group;
  • R E is selected from hydrogen and a substituted or unsubstituted C R C 4 alkyl group
  • Each substituted or unsubstituted group is either unsubstituted or each independently substituted with one or more (eg, 1 or 2 or 3) substituents, each substituent being independently selected from the group consisting of: - Mercapto, aryl, heteroaryl, aryl-C alkyl-, heteroaryl--alkyl-, C C4 halogenated fluorenyl-, -OV alkyl, -OC r C 4 hydrocarbon phenyl, - Ci-C 4 fluorenyl-OH, -OCVC 4 haloalkyl, halo, -OH, -NH 2 , -C alkyl-NH 2 , -N(C r C 4 fluorenyl) (alkyl), - NH(C r C 4 alkyl), Hydrocarbon phenyl), cyano, nitro, oxo (substituent as heteroaryl), -CO 2 H, -C(O)OCVC 4 flu
  • Substituted alkoxy refers to an alkoxy group whose alkyl moiety is substituted (eg, -O-(substituted fluorenyl), wherein “substituted fluorenyl” refers to one or more (may be more Up to 5, for example, up to 3) sulfhydryl groups in which a hydrogen atom is replaced by a substituent selected from the following groups:
  • R a is selected from a substituted or unsubstituted C r C 6 fluorenyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group;
  • R ⁇ AH a substituted or unsubstituted -C 6 alkyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group;
  • R e is selected from hydrogen and a substituted or unsubstituted CH alkyl group
  • Each substituted or unsubstituted group is either unsubstituted or each independently substituted with one or more (eg, 1 or 2 or 3) substituents, each substituent being independently selected from the group consisting of: CC 4- alkyl, aryl, heteroaryl, aryl-fluorenyl-, heteroaryl-C r C 4 alkyl-, CVC4 haloalkyl-, -OC r C 4 fluorenyl, -O-hydrocarbylphenyl, -CVC 4 alkyl-OH, -OC r C 4 halodecyl, halo, -OH, -NH 2 , -C r C 4 alkyl-NH 2 , -NC alkyl) (CVC 4 fluorenyl) ), -NH alkyl), -N(C r C 4 alkyl) (VC 4 hydrocarbon phenyl), -NH(dC 4 hydrocarbon phenyl), cyano,
  • a class of substituted alkoxy is "polymethoxy" or is expressed as -O-(substituted or unsubstituted alkylene)-(substituted or unsubstituted alkoxy), And includes some groups such as -OCH 2 CH 2 OCH 3 , some ethylene glycol esters such as polyethylene glycol, and -O(CH 2 CH 2 O) x CH 3 (where X is an integer of 2-20, for example, 2-10 and 2-5).
  • Another type of substituted indolyloxy group is hydroxymethoxy or is expressed as -OCH 2 (CH 2 ) y OH, where y is an integer from 1 to 10 (eg, 1-4).
  • Substituted oxime oxycarbonyl refers to a group of the structure (substituted alkyl)-O-C(0)-. The group is bonded to the parent structure through its carbonyl moiety, and the "substituted alkyl group" in the group means that one or more (up to 5, for example, up to 3) hydrogen atoms are from the following groups.
  • R a is selected from a substituted or unsubstituted C 6 fluorenyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group;
  • R A substituted or unsubstituted c alkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
  • R is selected from hydrogen and a substituted or unsubstituted C 4 alkyl group
  • Each substituted or unsubstituted group is either unsubstituted or each independently substituted with one or more (eg, 1 or 2 or 3) substituents, each substituent being independently selected from the group consisting of: C r C 4 alkyl, aryl, heteroaryl, aryl-CV alkyl-, heteroaryl-C r C 4 alkyl-, C r C4 halogenated fluorenyl-, -OC fluorenyl, -OC r C 4 hydrocarbon phenyl, -CC alkyl-OH, -OCi-haloalkyl, halo, -OH, -NH 2 , alkyl-NH 2 ,
  • Substituted amino refers to a group of the structure -NHR d or -NR d R d .
  • Each R d is each independently selected from the group consisting of a substituted or unsubstituted alkyl group, a substituted or unsubstituted cyclodecyl group, a substituted or unsubstituted acyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted group.
  • the three) hydrogen atoms are each independently replaced by a group selected from the following substituents:
  • -R a , -OR b , -0 CVC 2 fluorenyl) O- (for example, dioxin)
  • -SR b hydrazine, hydrazine in which one or more hydrogen atoms are replaced by a lower alkyl group
  • -NR b R. halogenated, cyano, nitro, -COR b , -CO 2 R b , -CONR b R.
  • R a is selected from a substituted or unsubstituted C 6 fluorenyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group;
  • ⁇ selected from 11, a substituted or unsubstituted c 6 fluorenyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group;
  • R e is selected from hydrogen and a substituted or unsubstituted C 4 fluorenyl group
  • Each substituted or unsubstituted group is either unsubstituted or each independently substituted with one or more (eg, 1 or 2 or 3) substituents, each substituent being independently selected from the group consisting of: C r C 4 alkyl, aryl, heteroaryl, aryl-dC 4 fluorenyl-, heteroaryl-Cr alkyl-, C r C4 haloalkyl-, -OC r C 4 fluorenyl, -OCVC 4 hydrocarbon Phenyl, -C decyl-OH, -OCVC 4 haloalkyl, halo, -OH, -NH 2 , -CC 4 fluorenyl-NH 2 , -N(CVC 4 fluorenyl) (fluorenyl), - NH C alkyl), -N(C r C 4 fluorenyl) (C hydrocarbon phenyl), -NH ⁇ -hydrocarbylphenyl), cyan
  • an effective dose means the amount of a chemical substance capable of producing a therapeutic effect on a disease when the chemical substance of the present invention is used in a patient.
  • an effective dose can be an amount sufficient to treat a chemical that inhibits a protein kinase.
  • the effective dose can be measured by testing, for example, by analyzing the concentration of chemicals in the blood.
  • the effective dose can also be theoretically calculated, for example, by calculating bioavailability.
  • “Significant” means that any detectable change is statistically significant. This statistical significance can be derived from a parametric or non-parametric hypothesis test, for example, Student's t-test gives a result of p ⁇ 0.05.
  • "Patient” means an animal (such as a human) that has or will be a subject of treatment, observation, or testing. The methods provided by the present invention can be beneficial for both human therapeutic and veterinary applications. In certain embodiments, the patient is a mammal. In yet other specific embodiments, the patient is a human.
  • Angiogenic protein kinase refers to a protein kinase involved in the process of angiogenesis, including but not limited to VEGFR2 and PDGFRp.
  • “Inhibition” refers to a decrease in the activity of a protein kinase which is directly or indirectly caused by the presence of a compound represented by the formula (I), and the decrease in the activity of the kinase is relative to the activity of the kinase in the absence of the compound. This decrease in activity may be due to a direct interaction of the compound with the protein kinase, or due to the interaction of the compound with one or more other factors that affects the activity of the kinase.
  • the presence of a compound can reduce its activity by binding directly to a protein kinase, or by (directly or indirectly) causing another factor to reduce the activity of a protein kinase, or by (directly or indirectly) reducing a protein kinase in a cell or organism.
  • the content in the medium can reduce its activity by binding directly to a protein kinase, or by (directly or indirectly) causing another factor to reduce the activity of a protein kinase, or by (directly or indirectly) reducing a protein kinase in a cell or organism.
  • Treatment refers to any treatment of a patient's condition, including: prevention of the disease, ie, the clinical symptoms of the disease cease to develop; inhibition of the disease; slowing or blocking the development of clinical symptoms; and alleviating the disease, which causes the deterioration of clinical symptoms.
  • Diseases that are responsive to inhibition of protein kinases refers to pathological conditions that are at least partially dependent on the activity of one or more protein kinases (e.g., angiogenic protein kinases). Protein kinases are involved directly or indirectly in signaling pathways for various cellular activities, such as cell division, differentiation, and migration. Diseases that are responsive to inhibition of protein kinases include, but are not limited to, tumor growth, growth of solid tumors supported by angiogenesis, and diseases characterized by excessive local vascular growth (e.g., diabetic retinopathy, macular degeneration, and inflammation).
  • the present invention provides a diphenylurea derivative represented by the formula (I), and pharmaceutically acceptable salts, solvates, crystals, chelating agents, non-covalent complexes, prodrugs, and mixtures thereof,
  • X, and X 2 are each independently selected from CH and N;
  • R7 is a substituted or unsubstituted aryl or heteroaryl group;
  • Z is -, where:
  • ⁇ ⁇ 3 is - CR 9 R 1Q -, where R 9 and. Each independently selected from a hydrogen atom, a substituted or unsubstituted dC 3 alkyl group, and a halogen;
  • Z 2 is absent or is selected from -O-, -S -, -NR -, wherein R is selected from H and C 3 alkyl;
  • n and m are integers from 0 to 2; '
  • R1 is absent or represents 1, 2 or 3 substituents, each substituent being independently selected from the group consisting of hydroxyl, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl, halo, carboxy , substituted or unsubstituted acyl group, substituted or unsubstituted alkoxycarbonyl group, substituted or unsubstituted fluorenyl group, substituted or unsubstituted C r C3 alkoxy group, sulfonyl group, sulfinyl group, sulfonyl group;
  • R4 is absent or represents 1, 2, 3, 4 or 5 substituents, each substituent being independently selected from the group consisting of: hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl , halo, carboxy, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted cvc 6 fluorenyl, substituted or unsubstituted ⁇ -0 6 decyloxy, a substituted or unsubstituted aryloxy group, a sulfonyl group, a sulfinyl group, a sulfonyl group, a substituted or unsubstituted arene group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted heterocycloalkyl group; Or an adjacent two R 4 groups together with the attached carbon atom form an aromatic ring,
  • R1 represents 0 or 1 or 2 or 3 substituents, wherein the substituents are independently selected from halo, CC 3 alkyl, and a group selected among CrC 3 embankment. In certain embodiments, R1 represents 1 or 2 or 3 substituents, wherein each substituent is independently selected from the group consisting of dentate, methyl, and methoxy. In certain embodiments, R1 represents a substituent selected from the group consisting of halo, methyl, and methoxy. In certain embodiments, R1 does not occur.
  • R.sup.4 represents 0 to 5 substituents, wherein each substituent is independently selected from the group consisting of: hydroxy, nitro, cyano, substituted or unsubstituted amino, halo, Carboxyl, substituted or unsubstituted -C 6 fluorenyl, substituted or unsubstituted ( ⁇ - ⁇ methoxy, substituted or unsubstituted phenoxy, C r C 6 alkoxysulfonyl, C r C 6 Acyl, C r C 6 ⁇ oxycarbonyl, substituted or unsubstituted heteroaryl, and heterocycloalkyl.
  • R.sup.4 represents 1 to 5 substituents, wherein each substituent is independently Among the following groups are selected: hydroxy, cyano, halo, substituted or unsubstituted dC 2 fluorenyl, phenoxy, substituted or unsubstituted -( 2 fluorenyloxy.
  • R.sup.4 represents 1 to 5 substituents, wherein each substituent is independently selected from the group consisting of halo, methyl, methoxy, ethoxy, and trifluoromethyl. .
  • R.sup.4 represents 3 substituents, wherein each substituent is independently selected from the group consisting of: hydrogen atom, halo, methyl, methoxy, ethoxy, and trifluoromethyl. And at least one of the three substituents is not a hydrogen atom.
  • R.sup.4 represents 2 substituents, wherein each substituent is independently selected from the group consisting of: hydrogen atom, halo, methyl, methoxy, ethoxy, and trifluoromethyl. And at least one of the two substituents is not a hydrogen atom.
  • R4 does not occur.
  • R7 is selected from the group consisting of pyrimidinyl and substituted pyrimidinyl, wherein the substituted pyrimidinyl is selected from the group consisting of mono-, di-, and tri-substituted pyrimidinyl groups, wherein each substituent is independently Selected from the group consisting of: hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl, halo, carboxy, substituted or unsubstituted acyl, substituted or unsubstituted fluorenyloxy, substituted Or unsubstituted ( ⁇ - ⁇ alkyl, substituted or unsubstituted-( 6 alkoxy, sulfonyl, sulfinyl, sulfonyl, substituted or unsubstituted arene, substituted or unsubstituted)
  • An aromatic hydrocarbon group a substituted or unsubstituted heterocyclic hydrocarbon group.
  • R7 is selected from the group consisting of pyrimidinyl and substituted pyrimidinyl, wherein substituted pyrimidinyl is selected from the group consisting of mono-, di-, and tri-substituted pyrimidinyl groups, wherein substituents on substituted pyrimidinyl groups Separately selected from the group consisting of: hydroxy, nitro, cyano, substituted or unsubstituted amino, halo, carboxy, substituted or unsubstituted cc 6 alkyl, substituted or unsubstituted c r c 6 methoxy, c r c 6 sulfonylamino, cc 6 acyl, c r c 6 alkoxycarbonyl, substituted or unsubstituted heteroaryl, and heterocycloalkyl.
  • R7 is selected from the group consisting of pyrimidinyl and substituted pyrimidinyl, wherein substituted pyrimidinyl is selected from the group consisting of mono-, di-, and tri-substituted pyrimidinyl groups, wherein substituents on substituted pyrimidinyl groups independently selected from the group consisting of: hydroxy, cyano, halo, a substituted or unsubstituted alkyl with C r C 2, and a substituted or unsubstituted ( ⁇ - ( ⁇ embankment group.
  • R7 is selected from pyrimidin-4-yl and substituted pyrimidin-4-yl, wherein substituted pyrimidin-4-yl is derived from mono-, di-, and tri-substituted pyrimidin-4-yl Selected as follows, wherein each substituent is independently selected from the group consisting of: hydroxy, nitro, aryl, substituted or unsubstituted amino, aminocarbonyl, halo, carboxy, substituted or unsubstituted acyl, substituted Or unsubstituted alkoxycarbonyl, substituted or unsubstituted C ⁇ group, substituted or unsubstituted ( ⁇ -( 6 alkoxy, sulfonyl, sulfinyl, sulfonyl, substituted or unsubstituted a substituted aromatic hydrocarbon group, a substituted or unsubstituted heteroaryl hydrocarbon group, a substituted or unsubstituted heterocycl
  • R7 is selected from pyrimidin-4-yl and substituted pyrimidin-4-yl, wherein substituted pyrimidin-4-yl is derived from mono-, di-, and tri-substituted pyrimidin-4-yl Selected from the substituents on the substituted pyrimidin-4-yl group, each independently selected from the group consisting of hydroxy, nitro, cyano, substituted or unsubstituted amino, halo, carboxy, substituted or unsubstituted Substituted C alkyl, substituted or unsubstituted -( 0 methoxy, -C 6 alkoxysulfonyl, C r C 6 acyl, C r C 6 alkoxycarbonyl, substituted or unsubstituted heteroaryl, And a heterocyclic hydrocarbon group.
  • R7 is selected from pyrimidin-4-yl and substituted pyrimidin-4-yl, wherein substituted pyrimidin-4-yl is derived from mono-, di-, and tri-substituted pyrimidin-4-yl Selected from the substituents on the substituted pyrimidin-4-yl group, each independently selected from the group consisting of hydroxy, cyano, halo, substituted or unsubstituted dC 2 alkyl, and substituted or unsubstituted -( 2 alkoxy.
  • R7' is pyrimidin-4-yl.
  • R7 is selected from the group consisting of pyridyl and substituted pyridyl, wherein the substituted pyridyl is selected from the group consisting of mono-, di-, and tri-substituted pyridyl groups, wherein each substituent is independently selected from The following groups: hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl, carboxy, substituted or unsubstituted acyl, substituted or unsubstituted fluorenyloxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, sulfonyl, sulfinyl, sulfonyl, substituted or unsubstituted arene, substituted or unsubstituted heteroaryl, substituted Or unsubstituted heterocycloalkyl.
  • R7 is selected from the group consisting of pyridinyl and substituted pyridyl, wherein the substituted pyridyl group is selected from the group consisting of mono-, di-, and tri-substituted pyridyl groups, wherein the substituent on the substituted pyridyl group Individually selected from the group consisting of: hydroxy, nitro, cyano, substituted or unsubstituted amino, halo, carboxy, substituted or unsubstituted C 6 alkyl, substituted or unsubstituted C alkane An oxy group, a Cr C 6 hydrocarbon sulfonamide group, a C Ce acyl group, a C alkoxycarbonyl group, a substituted or unsubstituted heteroaryl hydrocarbon group, and a heterocyclic hydrocarbon group.
  • R7 is selected from the group consisting of pyridinyl and substituted pyridyl, wherein the substituted pyridyl group is selected from the group consisting of mono-, di-, and tri-substituted pyridyl groups, wherein the substituent on the substituted pyridyl group
  • the substituted pyridyl group is selected from the group consisting of mono-, di-, and tri-substituted pyridyl groups, wherein the substituent on the substituted pyridyl group
  • Each of them is independently selected from the group consisting of a hydroxyl group, a cyano group, a halogenated group, a substituted or unsubstituted Cr C 2 alkyl group, and a substituted or unsubstituted -( 2 methoxy group.
  • R7 is selected from the group consisting of pyridin-4-yl and substituted pyridin-4-yl, wherein substituted pyridin-4-yl is derived from mono-, di-, and tri-substituted pyridin-4-yl Selected, wherein each substituent is independently selected from the group consisting of: hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl, halo, carboxy, substituted or unsubstituted acyl, substituted Or unsubstituted alkoxycarbonyl, substituted or unsubstituted c r c 6 ⁇ A substituted, unsubstituted or unsubstituted aryloxy group, a sulfonyl group, a sulfinyl group, a sulfonyl group, a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted hetero
  • R7 is selected from the group consisting of pyridin-4-yl and substituted pyridin-4-yl, wherein substituted pyridin-4-yl is derived from mono-, di-, and tri-substituted pyridin-4-yl
  • the substituents on the substituted pyridin-4-yl group are each independently selected from the group consisting of: a hydroxyl group, a nitro group, a cyano group, a substituted or unsubstituted amino group, a halogenated group, a carboxyl group, a substituted or an unsubstituted group.
  • CC 6 alkyl substituted or unsubstituted ( ⁇ - ⁇ alkoxy, C r C 6 alkoxysulfonyl, -C 6 acyl, CC 6 fluorenyloxycarbonyl, substituted or unsubstituted heteroaryl); And a heterocyclic hydrocarbon group.
  • R7 is selected from the group consisting of pyridin-4-yl and substituted pyridin-4-yl, wherein substituted pyridin-4-yl is derived from mono-, di-, and tri-substituted pyridin-4-yl Selected from the substituents wherein the substituted pyridin-4-yl group is independently selected from the group consisting of hydroxy, cyano, halo, substituted or unsubstituted cr c 2 alkyl, and substituted or Unsubstituted ( ⁇ -( 2 alkoxy).
  • R7 is pyridin-4-yl.
  • ⁇ and : ⁇ are both ⁇ .
  • 1 ⁇ and: 3 ⁇ 4 are (:11.
  • an aromatic ring, a heteroaryl ring, an indenyl ring or a heterofluorenyl ring formed by two adjacent R4 groups together with a carbon atom to which they are attached is a 5- or 6-membered ring having 1 or 2 heteroatoms selected from 0, S or N.
  • the aromatic ring, heteroaryl ring, indenyl ring or heteroalkyl ring is ring-bonded to the attached benzene to form a bicyclic system selected from the group consisting of benzofuran, benzothiophene, Anthracene, carbazole, quinoline, pyridazine, quinoxaline.
  • N and X 2 are CH, the R1 group is substituted at the 7 position of the indole ring, and the -NH-CO-NH- is substituted at the 4 position of the indole ring.
  • 1 is > ⁇ and X 2 is N
  • the R1 group is substituted at the 7 position of the benzimidazole ring
  • the -NH-CO-NH- is substituted at the 4 position of the indole ring.
  • Z is selected from -O-, -S -, CC 5 alkylene group, -NR -, wherein R is selected from H and C r C 3 alkyl.
  • the substituent -ZR7 has a structure represented by the formula (II),
  • R8 is absent or represents 1, 2, 3, 4 or 5 substituents, each substituent being independently selected from the group consisting of hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl, halogenated , a carboxy group, a substituted or unsubstituted acyl group, a substituted or unsubstituted fluorenyloxycarbonyl group, a substituted or unsubstituted C r C 6 alkyl group, a substituted or unsubstituted C r C 6 decyloxy group, a substituted or unsubstituted aryl group Oxyl, sulfonyl, sulfinyl, sulfonyl, substituted or unsubstituted arene, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl;
  • Y1 and Y2 are each independently selected from CH and N. '
  • R8 represents 1 to 5 substituents, wherein each substituent is independently selected from the group consisting of: hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl , halo, carboxy, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted c r c 5 alkyl, substituted or unsubstituted cc alkoxy, substituted Or unsubstituted aryloxy, sulfonyl, sulfinyl, sulfonyl, substituted or unsubstituted arene, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl.
  • R8 represents 1 to 5 substituents, wherein each substituent is independently selected from the group consisting of: hydroxy, cyano, substituted or unsubstituted amino, halo, substituted Or unsubstituted cvc 2 alkyl, phenoxy, ( ⁇ -( ⁇ alkoxy).
  • R.sup.8 represents 1 to 5 substituents, wherein each substituent is independently selected from the group consisting of substituted or unsubstituted amino, halo, methyl, methoxy, B. Oxyl, and trifluoromethyl.
  • R8 does not occur.
  • the compound has the structure shown by formula (III)
  • R8 is absent or represents 1, 2, 3, 4 or 5 substituents, each substituent being independently selected from the group consisting of: hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl, halogenated , a carboxy group, a substituted or unsubstituted acyl group, a substituted or unsubstituted fluorenyloxycarbonyl group, a substituted or unsubstituted group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, a sulfonyl group, a sulfinyl group a sulfonyl group, a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted heteroaryl hydrocarbon group, a substituted or unsubstituted heterocyclic hydrocarbon group;
  • Y, and Y 2 are each independently selected from CH and ⁇ ;
  • R5 and R6 are each independently selected from the group consisting of hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl, halo, carboxy, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, a substituted or unsubstituted c 3 alkyl group, a substituted or unsubstituted ( ⁇ -yloxy group, a sulfonyl group, a sulfinyl group, a sulfonyl group, a substituted or unsubstituted arene group, a substituted or unsubstituted heteroaryl group, And a substituted or unsubstituted heterocyclic hydrocarbon group.
  • R1 is the same as in the description of the compound represented by the chemical formula (I).
  • At least one of ⁇ ⁇ 2 is N.
  • At least one of ⁇ ⁇ 2 is N.
  • R5 and R6 are each independently selected from the group consisting of: a hydrogen atom, a halo, a methyl group, a trifluoromethyl group, a methoxy group, and an ethoxy group.
  • At least one of R5 and R6 is not a hydrogen atom.
  • R5 and R6 are each independently selected from the group consisting of halo, methyl, trifluoromethyl, methoxy, and ethoxy.
  • R.sup.8 represents 1 to 5 substituents, wherein each substituent is independently selected from the group consisting of: hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl, halo, carboxy, a substituted or unsubstituted acyl group, a substituted or unsubstituted alkoxycarbonyl group, a substituted or unsubstituted C r C 5 embankment group, a substituted or unsubstituted ( ⁇ - 5 alkoxy group, A substituted or unsubstituted aryloxy group, a sulfonyl group, a sulfinyl group, a sulfonyl group, a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted heteroaryl hydrocarbon group, a substituted or unsubstituted heterocyclic hydrocarbon group.
  • R8 represents from 1 to 5 substituents, wherein each substituent is independently selected from the group consisting of: hydroxy, cyano, amino, halo, substituted or unsubstituted CrC 2 alkyl, phenoxy, ( ⁇ -decyloxy).
  • R8 represents from 1 to 5 substituents, wherein each substituent is independently selected from the group consisting of amino, halo, methyl, methoxy, ethoxy, and trifluoro. methyl.
  • R8 does not occur.
  • the compound has the structure shown in formula (IV)
  • R8 is absent or represents 1, 2, 3, 4 or 5 substituents, each substituent being independently selected from the group consisting of hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl, halogenated , carboxy, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted cvc 6 alkyl, substituted or unsubstituted ( ⁇ -0 6 methoxy, substituted or unsubstituted aryl Oxyl, sulfonyl, sulfinyl, sulfonyl, substituted or unsubstituted arene, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl;
  • Y 2 are each independently selected from CH and ⁇ ;
  • R6 and R11 are each independently selected from the group consisting of hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl, halo, carboxy, substituted or unsubstituted acyl, substituted or unsubstituted alkane oxycarbonyl group, a substituted or unsubstituted C, -C 3 alkyl with, a substituted or unsubstituted - € 3 alkoxy group, a sulfonamide group, a sulfinyl group, a sulfonyl group, a substituted or unsubstituted aromatic hydrocarbon group, a substituted Or unsubstituted heteroaryl hydrocarbon group, and substituted or unsubstituted heterocyclic hydrocarbon group.
  • At least one of ⁇ ⁇ 2 is N.
  • At least one of Y1 and Y2 is N.
  • R6 and R11 are each independently selected from the group consisting of hydrogen atom, halo, methyl, trifluoromethyl, methoxy, and ethoxy.
  • At least one of R6 and R11 is not a hydrogen atom.
  • R6 and R11 are each independently selected from the group consisting of halo, methyl, trifluoromethyl, methoxy, and ethoxy.
  • R.sup.8 represents 1 to 5 substituents, wherein each substituent is independently selected from the group consisting of: hydroxy, nitro, cyano, substituted or unsubstituted amino, aminocarbonyl, Halogenated, carboxy, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted (V
  • C 5 alkyl substituted or unsubstituted ( ⁇ -( 5 alkoxy, substituted or unsubstituted aryloxy, sulfonyl, sulfinyl, sulfonyl, substituted or unsubstituted arene, substituted Or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl.
  • R.sup.8 represents 1 to 5 substituents, wherein each substituent is independently selected from the group consisting of: hydroxy, cyano, amino, 3 ⁇ 4, substituted or unsubstituted fluorenyl, Phenoxy group, C wide C 2 decyloxy group.
  • R8 represents from 1 to 5 substituents, wherein each substituent is independently selected from the group consisting of amino, halo, methyl, methoxy, ethoxy, and trifluoro. methyl.
  • R8 does not occur.
  • preferred chemistries of the invention comprise the following compounds:
  • the compounds represented by the various chemical formulas of the present invention include, but are not limited to, optical isomers, racemic isomers, and other mixtures of the compounds represented by the chemical formula. Moreover, the compounds also include Z- and E-form (or cis- and trans-) structures of compounds having a double bond therein. Individual enantiomers or diastereomers (e.g., optically active configurations) can be obtained by asymmetric synthesis or separation of racemic isomers. Separation of racemic isomers can be achieved by conventional means such as crystallization by addition of a separating agent, or by liquid chromatography using chiral symmetry high pressure liquid chromatography (chiral HPLC). )column.
  • the chemistry of the invention comprises all tautomeric forms of the compound.
  • Compounds of the invention also include, but are not limited to, all pharmaceutically acceptable forms of the compounds and compounds represented by the formulas shown.
  • Pharmaceutically acceptable forms of the compounds include: pharmaceutically acceptable salts, solvates, crystalline forms (including polymorphs and clathrates), chelating agents, non-covalent complexes, precursors Medicine, and mixture.
  • the compounds described herein occur in the form of a pharmaceutically acceptable salt.
  • the term "chemical substance” also includes pharmaceutically acceptable salts, solvates, crystalline forms, chelating agents, non-covalent complexes, prodrugs, and mixtures.
  • “Pharmaceutically acceptable salts” include, but are not limited to, mineral acid salts (eg, hydrochlorides, phosphates, diphosphates, hydrobromides, sulfates, sulfites, nitrates, etc.) and organic acids.
  • Salts eg malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethyl
  • Sulfonic acid salts benzoates, salicylates, stearates, and stearates (such as acetate and HOOC-(CH 2 ) n -COOH, where n is 0-4), etc.
  • pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonia.
  • the free base can be obtained by alkalizing an acidic salt solution.
  • the reaction product obtained is a free base
  • the free base can be dissolved in a suitable organic solvent and the solution is acid treated to obtain an addition salt, especially a pharmaceutically acceptable addition. salt.
  • prodrug also falls within the scope of the chemical substance, for example, an ester or an amide derivative of the compound represented by the formula (I).
  • Prodrug - the term includes any compound which, when administered to a patient, can be converted to a compound represented by formula (I).
  • a metabolic process in a patient converts a prodrug into a compound represented by formula (I).
  • Examples of prodrugs include, but are not limited to, functional groups in compounds represented by formula (I)
  • a similar derivative of acetate, formate, benzoate or the like e.g., hydroxy or amide group.
  • solvate refers to a chemical produced by the interaction of a compound and a solvent. Suitable solvates can be pharmaceutically acceptable solvates, for example, hydrates (including monohydrate and hemihydrate).
  • chelating agent refers to a chemical substance obtained by integrating a compound and a metal ion at two (or more) points.
  • non-covalent complex refers to a chemical produced by the interaction of one compound with another molecule in which no covalent bond is formed between the compound and the molecule. For example, this compositing can be achieved by van der Waals forces, hydrogen bonds, and electrostatic forces (also known as ionic bonds).
  • active substance is used to refer to a biologically active chemical. In certain embodiments, an “active substance” is a compound having pharmaceutical use. For example, an active substance can be an anti-tumor drug.
  • the compound represented by the formula (I) or a salt of the compound and other compounds in the present invention can be synthesized by an appropriate chemical reaction process.
  • the present invention will utilize the following reaction schemes and synthetic products as an example to illustrate this chemical reaction process. The description of this chemical reaction process will be apparent to those of ordinary skill in the art of organic synthesis.
  • XI is N or CH
  • X2 is H, F, CI or Br
  • compound 102 is first dissolved in an inert solvent such as THF (tetrahydrofuran) or cyclohexane hydrocarbon in an amount of 5 to 50 times that of compound 102 ( V/W); further adding a base such as NaH (sodium hydride), Na 2 CO 3 (sodium carbonate) or NaHCO 3 (sodium hydrogencarbonate) in an amount of 1 to 3 times (molar ratio) of the compound 102; After the reaction mixture is completely dissolved, 1 to 1.5 times the molar ratio of the compound 103 is added thereto, and then the reaction is stirred at 0 ° C to 70 ° C for 2 hr to 24 hr ; after completion of the reaction, water is added and mixed, using AcOEt (ethyl acetate). The organic phase was extracted and further purified to give compound 104. Note: If the base used is NaH, the reaction temperature should be
  • the compound 104 is dissolved in a solvent of methanol, ethanol, ethyl acetate or a mixed solvent containing the same, and a catalyst M or Pd/C is added thereto, and hydrogenation is carried out at normal temperature and normal pressure (hydrogen pressure) for about 2 to 5 hr. After reduction, filtration and further purification afforded compound 105.
  • step 3 the third step (step 3 ):
  • compound 105 is dissolved in an inert solvent such as THF, cyclohexyl hydrocarbon, chloroform, dichloromethane or petroleum ether, the same molar ratio of compound 106 is added thereto, and then the reaction is stirred at 0 ° C to 40 ° C. 2hr ⁇ 24hr ; after completion of the reaction, water is added, filtered, and the organic phase is combined and further purified to obtain compound 107.
  • an inert solvent such as THF, cyclohexyl hydrocarbon, chloroform, dichloromethane or petroleum ether
  • step 4 the fourth step (step 4 ):
  • V volume, in milliliters (ml); W: weight, in units (g) ; Boc: tert-butoxycarbonyl, a protecting group for an amino group.
  • the intracellular portion of the receptor kinase containing the intact kinase active center in the VEGFR2 (KDR) and PDGFR P proteins was first cloned and expressed, and the cloned and expressed partial receptor kinase protein was preserved intact.
  • Kinase activity Analytical detection of receptor kinase activity can be performed by testing the activity of the purified partial receptor kinase protein using LanthaScreenT TR-FRET (Invitrogen).
  • the LanthaScreenTM TR-FRET assay can screen for certain compounds that are effective in inhibiting VEGFR2 (KDR) or/and PDGFR P kinase activity.
  • the compounds of the present invention may be formulated alone or in combination with one or more pharmaceutically acceptable carriers
  • a solvent, a diluent, or the like is administered for administration, and can be orally administered in the following dosage forms: tablets, capsules, dispersible powders, granules, for example, suspensions containing about 0.05-5% of a suspending agent, for example, 10-50% sugar.
  • the syrup and, for example, an elixir containing 20-50% ethanol, or the like, are administered parenterally in the form of a suspension in a sterile injectable solution or an isotonic medium containing about 0.05-5% of a suspending agent.
  • These pharmaceutical preparations may contain, for example, from about 0.05% to about 90% of the active ingredient in combination with the carrier, more usually from 5% to 60% by weight.
  • compositions comprising at least one of the chemicals described herein and pharmaceutically acceptable salts thereof (particularly hydrochloride, methanesulfonate, tosylate, lactate, and glucuronate) And solvates, crystallization, chelating agents, non-covalent complexes, prodrugs, and mixtures, and at least one pharmaceutically acceptable excipient, or adjuvant, or carrier.
  • pharmaceutically acceptable salts thereof particularly hydrochloride, methanesulfonate, tosylate, lactate, and glucuronate
  • solvates, crystallization, chelating agents, non-covalent complexes, prodrugs, and mixtures and at least one pharmaceutically acceptable excipient, or adjuvant, or carrier.
  • the pharmaceutical composition of the present invention can be administered orally, such as a tablet or a capsule; in a non-oral infusion form (including intravenous, subcutaneous, intramuscular, intravenous drip, eye drop, inhalation or spray)
  • a non-oral infusion form including intravenous, subcutaneous, intramuscular, intravenous drip, eye drop, inhalation or spray
  • a sterile solution, a suspension or an emulsion it is applied in the form of a body surface, such as an ointment or an emulsion cream; or in the form of an anal plug, such as a suppository.
  • solid carriers for use in pharmaceutical compositions include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose, and kaolin, while liquid carriers include sterile water, polyethylene glycol, nonionic surfactants, and edibles.
  • Oils such as corn oil, peanut oil and sesame oil, which are suitable for the characteristics of the active ingredient and the particular form of administration desired.
  • Adjuvants such as flavoring agents, coloring agents, preservatives, and antioxidants such as vitamins £, ascorbic acid, BHT, and BHA, which are commonly used in the preparation of pharmaceutical compositions, may also be included in the compositions. From the standpoint of ease of preparation and administration, preferred pharmaceutical compositions are solid compositions, especially tablets and capsules filled with solid or liquid.
  • compositions can be prepared in a conventional manner using conventional excipients.
  • the solution or suspension of these active compounds as a free base or a pharmaceutically acceptable salt can be prepared in water to be mixed with a surfactant such as hydroxypropylcellulose, as administered parenterally or intraperitoneally.
  • Dispersions can also be prepared in glycerol, polyethylene glycol liquids, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions, and sterile powders for the preparation of sterile injectable solutions or dispersions.
  • the dosage form must be sterile and liquid for injection. It must be stable under the conditions of manufacture and storage and must be resistant to microbial contamination such as bacteria and fungi.
  • the carrier may be, for example, a solvent or dispersion medium containing water, ethanol, a polyol (e.g., glycerol, propylene glycol, and polyethylene glycol liquid), a suitable mixture thereof, and a vegetable oil.
  • compositions of the invention can be described in dosage units. In some embodiments, usually
  • a dose of 5 to 5000 mg/m 2 of body surface area is administered to a warm-blooded animal, for example, about 0.1 to 100 mg/kg.
  • a unit dosage within a certain range such as 1-100 mg/kg (preferably 1-60 mg/kg), is a conceivable dosage form of the drug which usually produces a therapeutic effect.
  • a unit dosage form such as a tablet or a capsule usually contains from 1 to 500 mg of the active ingredient.
  • the frequency of use of the drug varies depending on the compound used and the disease.
  • the drug is usually administered 4 times or less.
  • the number of doses may also be one to two times per day.
  • the present invention also proposes the use of a compound represented by the formula (I) or a pharmaceutically acceptable salt, solvate, crystallization, chelating agent, non-covalent complex, prodrug, or mixture thereof for the treatment of a disease.
  • the disease to be treated should be responsive to inhibition of protein kinase activity in human or animal body due to treatment.
  • the compounds described herein have an inhibitory effect on at least one of VEGFR2 and PDGFR ⁇ . Therefore they are very valuable for anti-vascular growth. In certain embodiments, certain compounds have an inhibitory effect on both VEGFR2 and PDGFR P kinases. Therefore, these compounds are also valuable for anti-angiogenesis.
  • the present invention further provides a compound represented by the formula (I) or a pharmaceutically acceptable salt, solvate, crystal, chelating agent, non-covalent complex, prodrug or mixture thereof as a medicament.
  • Anti-angiogenic effects are produced in warm-blooded animals (including humans).
  • the present invention further proposes that the compound represented by the formula (I) or a pharmaceutically acceptable salt, solvate, crystal, chelating agent, non-covalent complex, prodrug or mixture thereof can be used for the manufacture of warm blood.
  • An animal such as a human that produces an anti-angiogenic effect in the body.
  • the invention further proposes a method for producing an anti-angiogenic effect in a warm-blooded animal such as a human.
  • the method wherein: the animal is in need of anti-angiogenic therapy, and the therapy comprises: administering an effective amount of the compound represented by the formula (I) or a pharmaceutically acceptable salt, solvate, crystal, chelating agent, non- A covalent complex, prodrug, or mixture is used on the animal.
  • the size of the dose required for the treatment or prophylaxis of a particular disease needs to be adjusted accordingly, depending on the subject being treated, the route of administration, and the severity of the condition being treated.
  • the daily dose is controlled in the range of 1 to 60 mg/kg.
  • the daily dose must be adjusted depending on the subject being treated, the route of administration, and the severity of the condition. Therefore, the optimal dose should be determined by the doctor or nurse treating the patient.
  • the anti-angiogenic therapy as defined above may be used alone as a treatment or in combination with one or more other substances or therapies as a treatment.
  • This combination therapy can be achieved by performing a single therapy in combination therapy simultaneously, sequentially or completely separately.
  • oncology treatment it is common to use a variety of different treatments to treat cancer patients.
  • other common constitutional therapies include surgery, radiation therapy, and chemotherapy.
  • the chemistry of at least one of the compounds represented by Formula 00, or a pharmaceutically acceptable salt, solvate, crystallization, chelate, non-covalent complex, prodrug, and mixtures thereof is combined with the other at least one reactive monomer in a single dose.
  • Antitumor drugs for radiation therapy can be used alone or in combination with chemotherapy drugs.
  • Suitable anti-tumor therapies that can be used in combination with at least one of the above-described chemicals are as follows.
  • examples of such anti-tumor therapies include: microtubule stabilizers such as paclitaxel (trade name Taxol), polyene melamine (trade name Taxotere), epothilone A, epothilone Epothilone B, desoxyepothilone A. deoxyepothilone B or derivatives thereof; microtubule disrupting agent; alkylating agent; antimetabolite; An anti-neoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum complex; biological effect modifier; growth inhibitory factor; hormone/antihormone therapeutic and hematopoietic growth factor.
  • microtubule stabilizers such as paclitaxel (trade name Taxol), polyene melamine (trade name Taxotere), epothilone A, epothilone Epothilone B, desoxyepothilone A. deoxyepothilone B or derivatives thereof
  • Examples of typical anti-tumor therapies include: anthracyclines, vinca, mitomycins, spectinomycins, cytotoxic nucleosides, taxanes, epothilones, discoderm 0 lide, The pteridine drugs, diyn enes , podophyllotoxins; preferred in these examples are doxorubicin, noredamycin , daunorubicin, alanine, methotrexate, Methyl folate, ampicillin, mitomycin (, methyl mitomycin, her Ce ptin, 5-fluorouracil, 6-mercaptopurine, 2,2-difluorodeoxygenation Cytosine, cytarabine, podophyllotoxin or podophyllotoxin (such as scorpion scorpion, ghost white sulphur phosphate, ghost thiophene) ⁇ ), melphalan, vinblastine, vincristine, isovinblastine, vindesine, vinor
  • anti-tumor agents include estramustine, cisplatin, carboplatin, cyclophosphamide, bleomycin, tamoxifen, isophosphoramide, hexamethyl melamine, triethylene thiophosphoramide, idatr exa te, Trimetrexate, carbazole, L-asparaginase, camptothecin, CPT-11, topotecan, cytarabine, bicalutamide, flutamide, leuprolide acetate, pyridinium And pyrrole derivatives, interferons and interleukins.
  • At least one of the compounds represented by formula (I) or a pharmaceutically acceptable salt, solvate, crystal, chelate, non-covalent complex, prodrug thereof, and mixtures thereof can be administered in combination with an anti-inflammatory agent (anti-inflammatory drug).
  • Anti-inflammatory drugs include NSAIDs (non-steroidal anti-inflammatory drugs), non-specific and COX-2 (epoxidase 2)-specific cyclooxygenase inhibitors, gold-containing compounds, corticosteroids, methotrexate, Tumor necrosis factor (TNF) receptor antagonists, immunosuppressive agents and methotrexate.
  • NSAIDs non-anti-inflammatory drugs
  • ibuprofen include ibuprofen, flurbiprofen, naproxen and naproxen sodium, diclofenac, sodium diclofenac complex, misoprostol, sulindac, oxaprozin, Diflunisal, piroxicam, indomethacin, etodolac, fenoprofen, ketoprofen, nabumetone, sulfamethazine, tolbutine sodium and hydroxychloroquine.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • COX-2 epoxidase 2-specific inhibitors
  • the anti-inflammatory agent can also be a salicylate; the salicylate comprises acetylsalicylic acid (aspirin), sodium salicylate, magnesium salicylate, and choline.
  • the anti-inflammatory agent may also be a corticosteroid such as cortisone, dexamethasone, methylprednisolone, dehydrocortisone, dehydrocortisone sodium phosphate and prednisone.
  • the anti-inflammatory agent can be a gold-containing compound such as gold, thiomalic acid or auranofin sodium.
  • the anti-inflammatory agent can also be a metabolic inhibitor such as a dihydrofolate reductase inhibitor, aminomethylfolate or a dihydroorotate dehydrogenase inhibitor, leflunomide.
  • Certain embodiments of the invention also include certain co-administrations wherein the anti-inflammatory agent used may be an anti-C5 monoclonal antibody (e.g., eculizumab or pexelizumab), and TNF (tumor necrosis factor) may be anti-qi (e.g., entanercept or infliximab) (Infliximab)), an anti-TNF a monoclonal antibody, or at least one of immunosuppressive agents such as methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine Or an active compound of mycophenolate mofetil.
  • TNF tumor necrosis factor
  • Vascular growth is a process of forming new blood vessels based on existing blood vessels. Since blood vessels grow in many pathological states (including but not limited to tumors (Gasparini, G. et al., 2005), chronic inflammation (Konno, S. et al., 2004; Suthin, K. et al., 2003; Medina, J. et al. People, 2005), diabetic retinopathy (Campochiaro 5 P. A, 2004), and macular degeneration (Rothen, M.
  • the chemicals described in the present invention will be against many diseases.
  • the treatment is effective.
  • the chemicals described herein will be effective in slowing the growth of solid tumors (e.g., rectal cancer, breast cancer, prostate cancer, kidney cancer, lung cancer, and skin cancer). More particularly, the chemicals described herein will be effective in inhibiting the growth of solid tumors associated with VEGFR2 and/or PDGFR P. This inhibition of solid tumor growth will be particularly effective when tumor growth and proliferation are dependent on VEGFR2 and/or PDGFR 0 (see review Gasparini, G. et al., 2005).
  • the physiological conditions and diseases in which the compound represented by the formula (I) and the pharmaceutical composition containing the compound are capable of producing effects include, but are not limited to, psoriasis, blood vessel growth, tumor (for example, chronic granulocyte Leukemia, gastrointestinal stromal cancer, non-small cell lung cancer, breast cancer, ovarian cancer, recurrent ovarian cancer, prostate cancer, especially hormone-refractory prostate cancer, kidney cancer, head and neck cancer, or rectal cancer), immune regulation ( Graft rejection), atherosclerosis, rheumatoid arthritis, Parkinson's disease, Alzheimer's disease, diabetes (such as type 2 diabetes and diabetic retinopathy), septic shock, and so on.
  • tumor for example, chronic granulocyte Leukemia, gastrointestinal stromal cancer, non-small cell lung cancer, breast cancer, ovarian cancer, recurrent ovarian cancer, prostate cancer, especially hormone-refractory prostate cancer, kidney cancer, head and neck cancer, or rectal cancer
  • immune regulation graft rejection
  • the compound represented by the formula (I) or a pharmaceutically acceptable salt, solvate, crystal, chelate, non-covalent complex, prodrug thereof and mixtures thereof may also be used.
  • ex vivo testing systems can be used to assess the effects of inhibitors of VEGFR2 and/or PDGFR kinase activity in test animals such as cats, dogs, rabbits, monkeys, rats, and mice.
  • test animals such as cats, dogs, rabbits, monkeys, rats, and mice.
  • IC 50 concentration required to produce a 50% inhibitory effect
  • TFA trifluoroacetic acid Implementation 1. Synthesis of the compound N-(2-Fluoro-5-bromo-phenyl)-N'-[l-(3-amino-methylenebenzene)imidazole-4]-urea
  • 4-nitro-1-(3-tert-butoxycarbonylamino-methylenebenzene)-benzimidazole 5.0 g (0.031 mol) 4-nitro-benzimidazole, dissolved in 200 ml of cyclohexane, ice bath Cool to 0 ° C, add 1.2 g (0.045 mol) of NaH (90%) with stirring, and keep for 0.5 hr; slowly add 10.5 g (0.037 mol) of 3-tert-butoxycarbonylamino-bromobenzyl, and then react at room temperature.
  • N-(2-Fluoro-5-bromo-phenyl)-N'-[l-(3-tert-butoxycarbonylamino-methylenebenzene)-benzimidazole-4]-urea 5.9 g (0.017 mol) 4-Amino-1-(3-tert-butoxycarbonylamino-methylenebenzene)-benzimidazole, dissolved in 60 ml of dichloromethane, cooled to 0 ° C in an ice bath, and slowly added 3.7 g (0.017 mol) 2-Fluoro-5-bromo-isocyanate benzene, and reacted at room temperature for 24 hr ; after completion of the reaction, 50 ml of water was added, filtered, and washed with a small amount of cold dichloromethane to give a white solid; Filtration to -10 ° C, and washed with a little cold dichloromethane to give a white solid.
  • N-(2-Fluoro-5-bromo-phenyl)-N'-[l-(3-amino-methylenebenzene)-benzimidazole-41-urea In 12 ml TFA, add 4.5 g (0.0081 Mol) N-(2-fluoro-5-bromo-phenyl)-N'-[l-(3-tert-butoxycarbonylamino-methylenebenzene)-benzimidazole-4]-urea, at room temperature The reaction was carried out for 0.75 hr. After the reaction mixture was evaporated to dryness elution elution elution elution elution elution elution elution elution elution elution elution elution elution elution elution elution elution elution elution elution elution elution elution elution elution
  • the Finnigan LCQ DECA XP Ion Well Mass Spectrometer connected to the Agilent 1100 HPLC uses an electronic spray ion source.
  • the instrument carries a LockSpray source for accurate quality measurements.
  • the resolution of the mass spectrometer was adjusted to 5000 (FWHM) for acquisition of a positive ion mode mass spectrum between 100-100 ODA.
  • Leucine enkephalin (556.2771 [M+H]+) was used to provide a mass reference. Table 1
  • the VEGFR2 (KDR) protein used in the inhibitor screening assay contains only the portion of the receptor protein that is exposed to the cytoplasm, i.e., the portion of the amino acid sequence since the methionine at position 806.
  • the PDGFR P protein used in the experiment contained the tyrosine kinase domain part of the receptor protein. Since these two partial proteins are functionally equivalent to their overall structure, they are used instead of their overall structure for testing compounds for inhibition of protein kinase activity (Oncogene, 1990, 5: 519-524).
  • the cDNA molecules were first cloned and isolated (Molecular Cloning: A Laboratory Manual, Sambrook et al., 1989), and the desired cDNA fragment was cloned into the insect baculovirus.
  • the vector (baculoviurs vector) was used for subsequent protein expression and purification (The Baculovirus Expression System: A Laboratory Guide, LA King and RD Possee, Chapman and Hall, 1992).
  • VEGFR2 and PDGFR P protein kinases were performed according to published standard operating procedures. After passing the enzyme activity test, each batch of newly acquired protein kinase was divided into small portions and then refrigerated in a -70 C environment. In the enzyme activity test, the protein kinase was diluted to a different concentration using an enzyme dilution buffer to use 'the active concentration of the titration enzyme solution. In general, first prepare the IX enzyme buffer, that is, add 4 ml of 5X enzyme buffer and other reactants required by the kinase, such as MnCl, DTT, and calmodulin, to a certain container, and finally dilute with water to the end. The volume is 20 ml. The protein kinase used in the test was diluted with the above IX enzyme buffer at a ratio of 1 to 2000, and 50 ⁇ l of the diluted kinase solution was added to each well of a 96-well reaction plate for testing.
  • IX enzyme buffer that is,
  • Invitrogen's ⁇ '-LYTE Protein Kinase Test Kit (Part# PV3192) is used for high-throughput screening of compounds. Before performing screening experiments, various experimental parameters such as reaction time, incubation must be determined and optimized. Temperature, and the concentration of protein kinase and ATP required, thus The greatest degree of substrate phosphorylation should be obtained. First, the compound to be tested was carefully dissolved in DMSO to a concentration of 10 mM, and the solution was stored in an environment of - 20 C. At the same time, the substrate solution was prepared by diluting Poly-Glu, Ala, and Tyr (Sigma P3899) to a concentration of 1 mg/ml in a ratio of 1:500 with PBS.
  • the diluted substrate solution of ⁇ was added to each well of a 96-well reaction plate, and the reaction plate was sealed and placed in 4C overnight. On the next day, the substrate solution was discarded and the wells were washed once with PBST (PBS containing 0.05% (v/v) TWEEN20), and the following substances were added to each well in order: 2.5 ⁇ l of 4X compound solution ( In 4% DMSO), 5 ⁇ l of kinase/polypeptide substrate mixture solution, and 4 ⁇ ⁇ solution.
  • PBST PBS containing 0.05% (v/v) TWEEN20
  • the final total reaction volume reached 10 ⁇ l.
  • the porous reaction plate was shaken to mix the kinase reaction in each well, and then reacted at room temperature for one hour. Next, 5 ⁇ l of development solution was added to each reaction and the reaction was continued for one hour. Finally, 5 ⁇ l of stop reagent was added to each reaction to stop the reaction.
  • the fluorescent signal generated in each reaction can be measured by a suitable fluorometer. Relevant experimental data such as fluorescence emission ratio, percent phosphorylation of the polypeptide substrate, Z, factor value, etc. can be calculated according to the method provided by the test kit.
  • the inhibitory effect of the compound of Example 2 on VEGFR2 and PDGFR protein kinase activity was tested by the above method (results are shown in Table 2 below), and some of the compounds exhibited an inhibitory effect on VEGFR2 protein kinase activity with a ⁇ or lower IC50. value.
  • inhibition of PDGFR P protein kinase activity by certain compounds showed an IC50 value of ⁇ or lower.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne les dérivés de diphénylurée de formule générale (I), ainsi que des sels, solvates ou promédicaments de ceux-ci, acceptables d'un point de vue pharmaceutique. Ces composés présentent des activités biologiques efficaces d'inhibition du VEGFR2 et/ou du PDGRF β.
PCT/CN2007/001227 2006-04-19 2007-04-16 Dérivés de diphénylurée utilisés comme inhibiteurs de kinase, compositions et utilisations de ceux-ci WO2007121662A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610025821.6 2006-04-19
CN2006100258216A CN101058561B (zh) 2006-04-19 2006-04-19 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途

Publications (1)

Publication Number Publication Date
WO2007121662A1 true WO2007121662A1 (fr) 2007-11-01

Family

ID=38624546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/001227 WO2007121662A1 (fr) 2006-04-19 2007-04-16 Dérivés de diphénylurée utilisés comme inhibiteurs de kinase, compositions et utilisations de ceux-ci

Country Status (2)

Country Link
CN (1) CN101058561B (fr)
WO (1) WO2007121662A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511575A (ja) * 2008-12-12 2012-05-24 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのアザインドール誘導体
EP2470533A1 (fr) * 2009-08-24 2012-07-04 Ascepion Pharmaceuticals, Inc. Composés d'urée contenant un groupe hétéroaryle 5,6-bicyclique
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
US9006241B2 (en) 2011-03-24 2015-04-14 Noviga Research Ab Pyrimidine derivatives
US10793551B2 (en) 2017-10-19 2020-10-06 Effector Therapeutics Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536806A (ja) * 2010-09-01 2013-09-26 アスセピオン ファーマスーティカル、インコーポレイテッド キナーゼ阻害剤としての重水素化複素環式化合物
CN105348168B (zh) * 2015-11-06 2018-04-10 厦门大学 1‑(2‑(金刚烷‑1‑基)‑1h‑吲哚‑5‑基)‑3‑取代脲衍生物及制备和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055484A1 (fr) * 2001-12-26 2003-07-10 Bayer Healthcare Ag Derives d'uree
WO2005009961A2 (fr) * 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
WO2006033943A2 (fr) * 2004-09-17 2006-03-30 Exelixis, Inc Modulateurs de kinases a base de pyrazole et leurs procedes d'utilisation
WO2006076593A1 (fr) * 2005-01-14 2006-07-20 Cgi Pharmaceuticals, Inc. Urees a substitution 1,3-diaryle, modulateurs de l'activite de kinases
WO2007024294A2 (fr) * 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certains urees substitues, modulateurs de l'activite des kinases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163691A (zh) * 2005-01-14 2008-04-16 Cgi药学股份有限公司 作为激酶活性调节剂的1,3-二芳基取代的脲

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055484A1 (fr) * 2001-12-26 2003-07-10 Bayer Healthcare Ag Derives d'uree
WO2005009961A2 (fr) * 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
WO2006033943A2 (fr) * 2004-09-17 2006-03-30 Exelixis, Inc Modulateurs de kinases a base de pyrazole et leurs procedes d'utilisation
WO2006076593A1 (fr) * 2005-01-14 2006-07-20 Cgi Pharmaceuticals, Inc. Urees a substitution 1,3-diaryle, modulateurs de l'activite de kinases
WO2007024294A2 (fr) * 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certains urees substitues, modulateurs de l'activite des kinases

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511575A (ja) * 2008-12-12 2012-05-24 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのアザインドール誘導体
US8912330B2 (en) 2008-12-12 2014-12-16 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
EP2470533A1 (fr) * 2009-08-24 2012-07-04 Ascepion Pharmaceuticals, Inc. Composés d'urée contenant un groupe hétéroaryle 5,6-bicyclique
EP2470533A4 (fr) * 2009-08-24 2013-01-23 Ascepion Pharmaceuticals Inc Composés d'urée contenant un groupe hétéroaryle 5,6-bicyclique
JP2013502444A (ja) * 2009-08-24 2013-01-24 アスセピオン ファーマスーティカル、インコーポレイテッド キナーゼ阻害剤としての５，６−ビシクロヘテロアリール含有尿素化合物
US8648086B2 (en) 2009-08-24 2014-02-11 Ascepion Pharmaceuticals, Inc. 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
US9006241B2 (en) 2011-03-24 2015-04-14 Noviga Research Ab Pyrimidine derivatives
US10793551B2 (en) 2017-10-19 2020-10-06 Effector Therapeutics Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2

Also Published As

Publication number Publication date
CN101058561A (zh) 2007-10-24
CN101058561B (zh) 2011-01-26

Similar Documents

Publication Publication Date Title
CN104125957B (zh) 取代的苄基吡唑
CA2660899C (fr) Derives de compose tricyclique utiles pour le traitement de troubles neoplastiques, de troubles inflammatoires et de troubles immunomodulatoires
CN102947305B (zh) 用于激酶调节的化合物和方法及其适应症
TWI433677B (zh) 雜環化合物及其用途
WO2018177403A1 (fr) Composé 1h-imidazo[4,5-h]quinazoline utilisé en tant qu'inhibiteur de protéine kinase
AU2018201896A1 (en) Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
TW201201803A (en) Chemical compounds
JP2016525075A (ja) ヘテロアリール置換ピラゾール類
CA2872933A1 (fr) Cycloalcenopyrazoles substitues en tant qu'inhibiteurs de bub1 pour le traitement du cancer
JP2005509639A (ja) ベンゾイミダゾール誘導体、およびｋｄｒキナーゼタンパク質阻害剤としてのその使用
JP2016536311A (ja) ヘテロアリール置換ピラゾール類
JP2009544602A (ja) サイクリン依存性キナーゼ阻害剤の医学的使用
WO2007121662A1 (fr) Dérivés de diphénylurée utilisés comme inhibiteurs de kinase, compositions et utilisations de ceux-ci
US9688662B2 (en) N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors
KR20220059496A (ko) 키나제 억제제로서 3,5-이치환된 피라졸 화합물 및 이의 용도
DK2504331T3 (en) A compound, specific new forms, to pharmaceutical compositions thereof, and methods of making and using
EP3590941A1 (fr) Composés de dioxane-quinazoline et de dioxane-quinoléine liés à un cycle aromatique substitués par de l'urée, leur procédé de préparation et leur utilisation
CN107383016A (zh) 含杂芳基酰胺结构的吡咯并嘧啶化合物的制备及应用
CN102108078B (zh) 1,4-取代酞嗪类化合物及其制备方法和用途
JP2021529175A (ja) Ｃｄｋ４／６活性阻害化合物の結晶形およびその使用
WO2024074497A1 (fr) Composé inhibiteur de parg
CN110467616B (zh) 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN107474039A (zh) 含三氮唑酮和咪唑的4-苯氧基取代喹啉类化合物及其应用
KR20240042619A (ko) 유기 피리딘-피라졸 화합물 및 이의 용도
CN110407839B (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07720800

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07720800

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC D.D. 24-02-009

122 Ep: pct application non-entry in european phase

Ref document number: 07720800

Country of ref document: EP

Kind code of ref document: A1